Interdisciplinary management of skin cancer

Abstract

The interdisciplinary treatment of skin cancer in the head and neck area requires close collaboration between different specialist disciplines. The most common non-melanoma skin cancer tumor entities are cutaneous squamous cell carcinoma and basal cell carcinoma as well as their precursor lesions. One of the less common tumors is Merkel cell carcinoma, which also occurs primarily in light-exposed areas and, in contrast to squamous and basal cell carcinoma, is more likely to metastasize. Due to the low tendency of basal cell carcinoma as well as cutaneous squamous cell carcinoma to metastasize, a cure can often be achieved by surgery. If the tumor growth exceeds certain levels it may require collaboration between dermatology and otorhinolaryngology. The primary goal of this interdisciplinary collaboration is to achieve a functional, cosmetically and aesthetically acceptable result in addition to adequate tumor treatment. Depending on the stage of the tumor and the clinical course, a case may be discussed in an interdisciplinary tumor board in order to determine a personalised, appropriate and adequate treatment concept for each patient, including prevention, therapy and follow-up.

Publication History

Article published online:
02 May 2024

• Literatur

• 1 Die Haut – Anatomie und Funktion | DKG. (o. D.) https://www.krebsgesellschaft.de/onko-internetportal/basis-informationen-krebs/krebsarten/hautkrebs/der-aufbau-der-haut.html
• 2 Braakhuis BJM, Tabor MP, Kummer JA. et al. A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res 2003; 63: 1727-1730
• 3 Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. British Journal of Dermatology 2012; 166: 1069-1080 DOI: 10.1111/j.1365-2133.2012.10830.x.
• 4 Rubin AI, Chen EH, Ratner D. Basal-Cell Carcinoma. New England Journal of Medicine 2005; 353: 2262-2269 DOI: 10.1056/NEJMra044151.
• 5 Peterson SC, Eberl M, Vagnozzi AN. et al. Basal Cell Carcinoma Preferentially Arises from Stem Cells within Hair Follicle and Mechanosensory Niches. Cell Stem Cell 2015; 16: 400-412 DOI: 10.1016/j.stem.2015.02.006.
• 6 Brantsch KD, Meisner C, Schönfisch B. et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008; 9: 713-720 DOI: 10.1016/S1470-2045(08)70178-5.
• 7 Heppt MV, Leiter U, Steeb T. et al. S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ – Kurzfassung, Teil 1: Diagnostik, Interventionen bei aktinischen Keratosen, Versorgungsstrukturen und Qualitätsindikatoren. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2020; 18: 275-294 DOI: 10.1111/ddg.14048_g.
• 8 Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000; 42: S23-S24 DOI: 10.1067/mjd.2000.103339.
• 9 Palaniappan V, Karthikeyan K. Bowen’s disease. Indian Dermatol Online J 2022; 13: 177 DOI: 10.4103/idoj.idoj_257_21.
• 10 Becker JC, Beer AJ, DeTemple VK. et al. S2k-Leitlinie – Merkelzellkarzinom – Update 2022. J Dtsch Dermatol Ges 2023; 21: 305-317 DOI: 10.1111/ddg.14930_g.
• 11 Becker JC, Stang A, DeCaprio JA. et al. Merkel cell carcinoma. Nat Rev Dis Primers 2017; 3: 17077 DOI: 10.1038/nrdp.2017.77.
• 12 Feng H, Shuda M, Chang Y. et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008; 319: 1096-1100 DOI: 10.1126/science.1152586.
• 13 Schrama D, Peitsch WK, Zapatka M. et al. Merkel Cell Polyomavirus Status Is Not Associated with Clinical Course of Merkel Cell Carcinoma. Journal of Investigative Dermatology 2011; 131: 1631-1638 DOI: 10.1038/jid.2011.115.
• 14 DeWane ME, Kelsey A, Oliviero M. et al. Melanoma on chronically sun-damaged skin: Lentigo maligna and desmoplastic melanoma. J Am Acad Dermatol 2019; 81: 823-833 DOI: 10.1016/j.jaad.2019.03.066.
• 15 Kallini JR, Jain SK, Khachemoune A. Lentigo Maligna: Review of Salient Characteristics and Management. Am J Clin Dermatol 2013; 14: 473-480 DOI: 10.1007/s40257-013-0044-6.
• 16 De Luca EV, Perino F, Di Stefani A. et al. Lentigo maligna: diagnosis and treatment. Giornale Italiano di Dermatologia e Venereologia 2020; 155 DOI: 10.23736/S0392-0488.18.06003-0.
• 17 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Melanoms, Langversion 3.3, 2020, AWMF Registernummer: 032/024OL, http://www.leitlinienprogramm[1]onkologie.de/leitlinien/melanom/(abgerufen am: 30.08.2023).
• 18 Helbig D, Ziemer M, Dippel E. et al. S1-Leitlinie Atypisches Fibroxanthom (AFX) und pleomorphes dermales Sarkom (PDS). JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2022; 20: 235-245 DOI: 10.1111/ddg.14700_g.
• 19 Persa OD, Loquai C, Wobser M. et al. Extended surgical safety margins and ulceration are associated with an improved prognosis in pleomorphic dermal sarcomas. Journal of the European Academy of Dermatology and Venereology 2019; 33: 1577-1580 DOI: 10.1111/jdv.15493.
• 20 Krebs in Deutschland für 2013/2014. 11. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Berlin, 2017 DOI: 10.17886/rkipubl-2017-007
• 21 Asgari MM, Moffet HH, Ray GT. et al. Trends in Basal Cell Carcinoma Incidence and Identification of High-Risk Subgroups, 1998-2012. JAMA Dermatol 2015; 151: 976 DOI: 10.1001/jamadermatol.2015.1188.
• 22 Schäfer I, Reusch M, Siebert J. et al. Health care characteristics of basal cell carcinoma in Germany: the role of insurance status and socio-demographic factors. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2014; 12: 803-811 DOI: 10.1111/ddg.12415.
• 23 Lang BM, Balermpas P, Bauer A. et al. S2k-Leitlinie Basalzellkarzinom der Haut – Teil 2: Therapie, Prävention und Nachsorge. J Dtsch Dermatol Ges 2019; 17: 214-231 DOI: 10.1111/ddg.13755_g.
• 24 Ling G, Ahmadian A, Persson Å. et al. PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene 2001; 20: 7770-7778 DOI: 10.1038/sj.onc.1204946.
• 25 Kricker A, Armstrong BK, English DR. et al. Does intermittent sun exposure cause basal cell carcinoma? a case-control study in Western Australia. Int J Cancer 1995; 60: 489-494 DOI: 10.1002/ijc.2910600411.
• 26 Kricker A, Weber M, Sitas F. et al. Early Life UV and Risk of Basal and Squamous Cell Carcinoma in New South Wales, Australia. Photochem Photobiol 2017; 93: 1483-1491 DOI: 10.1111/php.12807.
• 27 Rosso S, Zanetti R, Martinez C. et al. The multicentre south European study „Helios“. II: Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer 1996; 73: 1447-1454 DOI: 10.1038/bjc.1996.275.
• 28 Wehner MR, Shive ML, Chren M-M. et al. Indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis. BMJ 2012; 345: e5909-e5909 DOI: 10.1136/bmj.e5909.
• 29 Penn I. Cancers in Renal Transplant Recipients. Adv Ren Replace Ther 2000; 7: 147-156 DOI: 10.1053/rr.2000.5269.
• 30 Gambini D, Passoni E, Nazzaro G. et al. Basal Cell Carcinoma and Hedgehog Pathway Inhibitors: Focus on Immune Response. Front Med (Lausanne) 2022; 9: 893063 DOI: 10.3389/fmed.2022.893063.
• 31 Togsverd-Bo K, Lei U, Erlendsson AM. et al. Combination of ablative fractional laser and daylight-mediated photodynamic therapy for actinic keratosis in organ transplant recipients – a randomized controlled trial. British Journal of Dermatology 2015; 172: 467-474 DOI: 10.1111/bjd.13222.
• 32 Lewis KG, Weinstock MA. Trends in nonmelanoma skin cancer mortality rates in the United States, 1969 through 2000. J Invest Dermatol 2007; 127: 2323-2327 DOI: 10.1038/sj.jid.5700897.
• 33 Euvrard S, Kanitakis J, Claudy A. Skin Cancers after Organ Transplantation. New England Journal of Medicine 2003; 348: 1681-1691 DOI: 10.1056/NEJMra022137.
• 34 Ulrich C, Schmook T, Nindl I. et al. Cutaneous precancers in organ transplant recipients: an old enemy in a new surrounding. British Journal of Dermatology 2003; 149: 40-42 DOI: 10.1046/j.0366-077X.2003.05633.x.
• 35 https://www.krebsinformationsdienst.de/aktuelles/2023/weisser-hautkrebs-berufskrankheit.php.
• 36 Lichter MD. Therapeutic Ionizing Radiation and the Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma. Arch Dermatol 2000; 136: 1007 DOI: 10.1001/archderm.136.8.1007.
• 37 Sugita K, Yamamoto O, Suenaga Y. Seven Cases of Radiation-Induced Cutaneous Squamous Cell Carcinoma. J UOEH 2000; 22: 259-267 DOI: 10.7888/juoeh.22.259.
• 38 Leiter U, Heppt MV, Steeb T. et al. S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ – Kurzfassung, Teil 2: Epidemiologie, chirurgische und systemische Therapie des Plattenepithelkarzinoms, Nachsorge, Prävention und Berufskrankheit. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2020; 18: 400-413 DOI: 10.1111/ddg.14072_g.
• 39 Stang A, Becker JC, Nghiem P. et al. The association between geographic location and incidence of Merkel cell carcinoma in comparison to melanoma: An international assessment. Eur J Cancer 2018; 94: 47-60 DOI: 10.1016/j.ejca.2018.02.003.
• 40 Cohen LM. Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 1995; 33: 923-936 DOI: 10.1016/0190-9622(95)90282-1.
• 41 Fröhlich SM, Cazzaniga S, Kaufmann LS. et al. A Retrospective Cohort Study on Patients with Lentigo Maligna Melanoma. Dermatology 2019; 235: 340-345 DOI: 10.1159/000499689.
• 42 Connolly KL, Nehal KS, Busam KJ. Lentigo maligna and lentigo maligna melanoma: contemporary issues in diagnosis and management. Melanoma Manag 2015; 2: 171-178 DOI: 10.2217/mmt.15.3.
• 43 Whiteman DC, Watt P, Purdie DM. et al. Melanocytic Nevi, Solar Keratoses, and Divergent Pathways to Cutaneous Melanoma. JNCI Journal of the National Cancer Institute 2003; 95: 806-812 DOI: 10.1093/jnci/95.11.806.
• 44 Howard GR, Nerad JA, Carter KD. et al. Clinical Characteristics Associated With Orbital Invasion of Cutaneous Basal Cell and Squamous Cell Tumors of the Eyelid. Am J Ophthalmol 1992; 113: 123-133 DOI: 10.1016/S0002-9394(14)71523-5.
• 45 Leibovitch I, Mcnab A, Sullivan T. Et Al. Orbital Invasion by Periocular Basal Cell Carcinoma. Ophthalmology 2005; 112: 717-723 DOI: 10.1016/j.ophtha.2004.11.036.
• 46 Niazi ZBM, Lamberty BGH. Perineural infiltration in basal cell carcinomas. Br J Plast Surg 1993; 46: 156-157 DOI: 10.1016/0007-1226(93)90150-A.
• 47 Dubin N, Kopf AW. Multivariate risk score for recurrence of cutaneous basal cell carcinomas. Arch Dermatol 1983; 119: 373-377
• 48 Sun L, Chin R-I, Gastman B. et al. Association of Disease Recurrence With Survival Outcomes in Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck Treated With Multimodality Therapy. JAMA Dermatol 2019; 155: 442 DOI: 10.1001/jamadermatol.2018.5453.
• 49 Eigentler TK, Leiter U, Häfner H-M. et al. Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study. Journal of Investigative Dermatology 2017; 137: 2309-2315 DOI: 10.1016/j.jid.2017.06.025.
• 50 Slaughter DP, Southwick HW, Smejkal W. “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer 1953; 6: 963-968 DOI: 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q.
• 51 Braakhuis BJM, Tabor MP, Kummer JA. et al. A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res 2003; 63: 1727-1730
• 52 Braakhuis BJM, Tabor MP, Kummer JA. et al. A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res 2003; 63: 1727-1730
• 53 Andruska N, Mahapatra L, Brenneman RJ. et al. Reduced Wide Local Excision Margins are Associated with Increased Risk of Relapse and Death from Merkel Cell Carcinoma. Ann Surg Oncol 2021; 28: 3312-3319 DOI: 10.1245/s10434-020-09145-7.
• 54 Song Y, Azari FS, Tang R. et al. Patterns of Metastasis in Merkel Cell Carcinoma. Ann Surg Oncol 2021; 28: 519-529 DOI: 10.1245/s10434-020-08587-3.
• 55 Farley CR, Perez MC, Soelling SJ. et al. Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival. Ann Surg Oncol 2020; 27: 1978-1985 DOI: 10.1245/s10434-019-08187-w.
• 56 Schadendorf D, Lebbé C, zur Hausen A. et al. Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer 2017; 71: 53-69 DOI: 10.1016/j.ejca.2016.10.022.
• 57 Harms KL, Healy MA, Nghiem P. et al. Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System. Ann Surg Oncol 2016; 23: 3564-3571 DOI: 10.1245/s10434-016-5266-4.
• 58 Requena C, Manrique E, Nagore E. El lentigo maligno: actualización y claves en el diagnóstico y el tratamiento. Actas Dermosifiliogr 2023; 114: 413-424 DOI: 10.1016/j.ad.2023.02.019.
• 59 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Prävention von Hautkrebs, Langversion 2.1, 2021, AWMF Registernummer: 032/052OL, https://www.leitlinienprogramm[1]onkologie.de/leitlinien/hautkrebs-praevention/(abgerufen am: 29.07.2023)).
• 60 Grob JJ, Gaudy-Marqueste C, Guminski A. et al. Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas. Journal of the European Academy of Dermatology and Venereology 2021; 35: 2149-2153 DOI: 10.1111/jdv.17467.
• 61 Christensen E, Mjønes P, Grimstad Ø. et al. Diagnostic Accuracy in Subtyping Basal Cell Carcinoma by Clinical Diagnosis Compared with Punch Biopsy. Acta Dermato Venereologica 2014; 0 DOI: 10.2340/00015555-2448.
• 62 Roozeboom M, Kreukels H, Nelemans P. et al. Subtyping Basal Cell Carcinoma by Clinical Diagnosis Versus Punch Biopsy. Acta Dermato Venereologica 2015; 95: 996-998 DOI: 10.2340/00015555-2113.
• 63 Armstrong LTD, Magnusson MR, Guppy MPB. Risk factors for recurrence of facial basal cell carcinoma after surgical excision: A follow-up analysis. Journal of Plastic, Reconstructive & Aesthetic Surgery 2017; 70: 1738-1745 DOI: 10.1016/j.bjps.2017.04.006.
• 64 Humphreys TR, Shah K, Wysong A. et al. The role of imaging in the management of patients with nonmelanoma skin cancer. J Am Acad Dermatol 2017; 76: 591-607 DOI: 10.1016/j.jaad.2015.10.009.
• 65 Schmitz L, Kahl P, Majores M. et al. Actinic keratosis: correlation between clinical and histological classification systems. Journal of the European Academy of Dermatology and Venereology 2016; 30: 1303-1307 DOI: 10.1111/jdv.13626.
• 66 Wheller L, Soyer HP. Clinical Features of Actinic Keratoses and Early Squamous Cell Carcinoma 2015; 58-63
• 67 Akay BN, Kocyigit P, Heper AO. et al. Dermatoscopy of flat pigmented facial lesions: diagnostic challenge between pigmented actinic keratosis and lentigo maligna. British Journal of Dermatology 2010; 163: 1212-1217 DOI: 10.1111/j.1365-2133.2010.10025.x.
• 68 Huerta-Brogeras M, Olmos O, Borbujo J. et al. Validation of Dermoscopy as a Real-time Noninvasive Diagnostic Imaging Technique for Actinic Keratosis. Arch Dermatol 2012; 148: 1159 DOI: 10.1001/archdermatol.2012.1060.
• 69 Schmitz L, Gupta G, Stücker M. et al. Evaluation of two histological classifications for actinic keratoses –<scp>PRO</scp>classification scored highest inter-rater reliability. Journal of the European Academy of Dermatology and Venereology 2019; 33: 1092-1097 DOI: 10.1111/jdv.15580.
• 70 Fernández-Figueras MT, Carrato C, Sáenz X. et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. Journal of the European Academy of Dermatology and Venereology 2015; 29: 991-997 DOI: 10.1111/jdv.12848.
• 71 Stratigos A, Garbe C, Lebbe C. et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer 2015; 51: 1989-2007 DOI: 10.1016/j.ejca.2015.06.110.
• 72 de Bree R, Takes RP, Castelijns JA. et al. Advances in diagnostic modalities to detect occult lymph node metastases in head and neck squamous cell carcinoma. Head Neck 2015; 37: 1829-1839 DOI: 10.1002/hed.23814.
• 73 Liao L-J, Lo W-C, Hsu W-L. et al. Detection of cervical lymph node metastasis in head and neck cancer patients with clinically N0 neck—a meta-analysis comparing different imaging modalities. BMC Cancer 2012; 12: 236 DOI: 10.1186/1471-2407-12-236.
• 74 Walsh NM, Cerroni L. Merkel cell carcinoma: A review. J Cutan Pathol 2021; 48: 411-421 DOI: 10.1111/cup.13910.
• 75 Singh N, Alexander NA, Lachance K. et al. Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patients. J Am Acad Dermatol 2021; 84: 330-339 DOI: 10.1016/j.jaad.2020.07.065.
• 76 Jenkins LN, Howle JR, Veness MJ. Sentinel lymph node biopsy in clinically node-negative Merkel cell carcinoma: the Westmead Hospital experience. ANZ J Surg 2019; 89: 520-523 DOI: 10.1111/ans.15228.
• 77 Swetter SM, Tsao H, Bichakjian CK. et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 2019; 80: 208-250 DOI: 10.1016/j.jaad.2018.08.055.
• 78 Geisse J, Caro I, Lindholm J. et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50: 722-733 DOI: 10.1016/j.jaad.2003.11.066.
• 79 Roozeboom MH, Arits AHMM, Mosterd K. et al. Three-Year Follow-Up Results of Photodynamic Therapy vs. Imiquimod vs. Fluorouracil for Treatment of Superficial Basal Cell Carcinoma: A Single-Blind, Noninferiority, Randomized Controlled Trial. Journal of Investigative Dermatology 2016; 136: 1568-1574 DOI: 10.1016/j.jid.2016.03.043.
• 80 Arits AH, Mosterd K, Essers BA. et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 2013; 14: 647-654 DOI: 10.1016/S1470-2045(13)70143-8.
• 81 Peng Q, Warloe T, Berg K. et al. 5-Aminolevulinic acid-based photodynamic therapy. Cancer 1997; 79: 2282-2308 DOI: 10.1002/(SICI)1097-0142(19970615)79:12<2282::AID-CNCR2>3.0.CO;2-O.
• 82 Basset-Seguin N, Ibbotson SH, Emtestam L. et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 2008; 18: 547-553 DOI: 10.1684/ejd.2008.0472.
• 83 Szeimies R, Ibbotson S, Murrell D. et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology 2008; 22: 1302-1311 DOI: 10.1111/j.1468-3083.2008.02803.x.
• 84 Kuflik EG. Cryosurgery for Skin Cancer: 30-Year Experience and Cure Rates. Dermatologic Surgery 2004; 30: 297-300 DOI: 10.1111/j.1524-4725.2004.30090.x.
• 85 Har-Shai Y, Sommer A, Gil T. et al. Intralesional cryosurgery for the treatment of basal cell carcinoma of the lower extremities in elderly subjects: a feasibility study. Int J Dermatol 2016; 55: 342-350 DOI: 10.1111/ijd.13168.
• 86 Berking C, Hauschild A, Kölbl O. et al. Basal cell carcinoma. -treatments for the commonest skin cancer. Dtsch Arztebl Int 2014; 111: 389-395 DOI: 10.3238/arztebl.2014.0389.
• 87 Drucker AM, Adam GP, Rofeberg V. et al. Treatments of Primary Basal Cell Carcinoma of the Skin. Ann Intern Med 2018; 169: 456-466 DOI: 10.7326/M18-0678.
• 88 McKeown SR, Hatfield P, Prestwich RJ. et al. Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation. Br J Radiol 2015; 88: 20150405 DOI: 10.1259/bjr.20150405.
• 89 Dirschka T, Gupta G, Micali G. et al. Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. Journal of Dermatological Treatment 2017; 28: 431-442 DOI: 10.1080/09546634.2016.1254328.
• 90 Arcuri D, Ramchatesingh B, Lagacé F. et al. Pharmacological Agents Used in the Prevention and Treatment of Actinic Keratosis: A Review. Int J Mol Sci 2023; 24: 4989 DOI: 10.3390/ijms24054989.
• 91 Smolinski MP, Bu Y, Clements J. et al. Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361). J Med Chem 2018; 61: 4704-4719 DOI: 10.1021/acs.jmedchem.8b00164.
• 92 Blauvelt A, Kempers S, Lain E. et al. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. New England Journal of Medicine 2021; 384: 512-520 DOI: 10.1056/NEJMoa2024040.
• 93 Mendenhall WM, Amdur RJ, Hinerman RW. et al. Skin Cancer of the Head and Neck With Perineural Invasion. Am J Clin Oncol 2007; 30: 93-96 DOI: 10.1097/01.coc.0000251224.16075.60.
• 94 Lansbury L, Bath-Hextall F, Perkins W. et al. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ 2013; 347: f6153-f6153 DOI: 10.1136/bmj.f6153.
• 95 Fang LC, Lemos B, Douglas J. et al. Radiation monotherapy as regional treatment for lymph node-positive Merkel cell carcinoma. Cancer 2010; 116: 1783-1790 DOI: 10.1002/cncr.24919.
• 96 Farshad A, Burg G, Panizzon R. et al. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. British Journal of Dermatology 2002; 146: 1042-1046 DOI: 10.1046/j.1365-2133.2002.04750.x.
• 97 Trakatelli M, Morton C, Nagore E. et al. Update of the European guidelines for basal cell carcinoma management. European Journal of Dermatology 2014; 24: 312-329 DOI: 10.1684/ejd.2014.2271.
• 98 Kauvar ANB, Cronin T, Roenigk R. et al. Consensus for Nonmelanoma Skin Cancer Treatment. Dermatologic Surgery 2015; 41: 550-571 DOI: 10.1097/DSS.0000000000000296.
• 99 Gulleth Y, Goldberg N, Silverman RP. et al. What Is the Best Surgical Margin for a Basal Cell Carcinoma: A Meta-Analysis of the Literature. Plast Reconstr Surg 2010; 126: 1222-1231 DOI: 10.1097/PRS.0b013e3181ea450d.
• 100 Nahhas AF, Scarbrough CA, Trotter S. A Review of the Global Guidelines on Surgical Margins for Nonmelanoma Skin Cancers. J Clin Aesthet Dermatol 2017; 10: 37-46
• 101 Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol 1987; 123: 340-344
• 102 Bichakjian CK, Olencki T, Aasi SZ. et al. Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 2016; 14: 574-597 DOI: 10.6004/jnccn.2016.0065.
• 103 Möhrle M. Von der „mikroskopisch kontrollierten Chirurgie” zur „3D-Histologie” – eine Erfolgsgeschichte. Aktuelle Derm 2009; 35: 283-286 DOI: 10.1055/s-0029-1214845.
• 104 Chen OM, Kim K, Steele C. et al. Advances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma. Cancers (Basel) 2022; 14: 3720 DOI: 10.3390/cancers14153720.
• 105 Rowe De, Carroll Rj, Day Cl. Mohs Surgery Is the Treatment of Choice for Recurrent (Previously Treated) Basal Cell Carcinoma. J Dermatol Surg Oncol 1989; 15: 424-431 DOI: 10.1111/j.1524-4725.1989.tb03249.x.
• 106 Abramson AK, Krasny MJ, Goldman GD. Tangential Shave Removal of Basal Cell Carcinoma. Dermatologic Surgery 2013; 39: 387-392 DOI: 10.1111/dsu.12106.
• 107 Stratigos AJ, Garbe C, Dessinioti C. et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. Eur J Cancer 2020; 128: 60-82 DOI: 10.1016/j.ejca.2020.01.007.
• 108 Zhang J, Wang Y, Wijaya WA. et al. Efficacy and prognostic factors of adjuvant radiotherapy for cutaneous squamous cell carcinoma: A systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology 2021; 35: 1777-1787 DOI: 10.1111/jdv.17330.
• 109 Sahovaler A, Krishnan RJ, Yeh DH. et al. Outcomes of Cutaneous Squamous Cell Carcinoma in the Head and Neck Region With Regional Lymph Node Metastasis. JAMA Otolaryngology–Head & Neck Surgery 2019; 145: 352 DOI: 10.1001/jamaoto.2018.4515.
• 110 Porceddu SV, Bressel M, Poulsen MG. et al. Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial. Journal of Clinical Oncology 2018; 36: 1275-1283 DOI: 10.1200/JCO.2017.77.0941.
• 111 Han AY, Patel PB, Anderson M. et al. Adjuvant radiation therapy improves patient survival in early-stage merkel cell carcinoma: A 15-year single-institution study. Laryngoscope 2018; 128 1862-1866 DOI: 10.1002/lary.27031.
• 112 Hazan C, Dusza SW, Delgado R. et al. Staged excision for lentigo maligna and lentigo maligna melanoma: A retrospective analysis of 117 cases. J Am Acad Dermatol 2008; 58: 142-148 DOI: 10.1016/j.jaad.2007.09.023.
• 113 Iznardo H, Garcia-Melendo C, Yélamos O. <p>Lentigo Maligna: Clinical Presentation and Appropriate Management</p>. . Clin Cosmet Investig Dermatol 2020; Volume 13: 837-855 DOI: 10.2147/CCID.S224738.
• 114 Robinson JK. Actinic Cheilitis: A Prospective Study Comparing Four Treatment Methods. Archives of Otolaryngology – Head and Neck Surgery 1989; 115: 848-852 DOI: 10.1001/archotol.1989.01860310086029.
• 115 Lai M, Pampena R, Cornacchia L. et al. Treatments of actinic cheilitis: A systematic review of the literature. J Am Acad Dermatol 2020; 83: 876-887 DOI: 10.1016/j.jaad.2019.07.106.
• 116 Perea-Milla López E, Miñarro-del Moral RM, Martínez-García C. et al. Lifestyles, environmental and phenotypic factors associated with lip cancer: a case–control study in southern Spain. Br J Cancer 2003; 88: 1702-1707 DOI: 10.1038/sj.bjc.6600975.
• 117 Wang DM, Kraft S, Rohani P. et al. Association of Nodal Metastasis and Mortality With Vermilion vs Cutaneous Lip Location in Cutaneous Squamous Cell Carcinoma of the Lip. JAMA Dermatol 2018; 154: 701 DOI: 10.1001/jamadermatol.2018.0792.
• 118 Gooris PJJ, Vermey A, de Visscher JGAM. et al. Supraomohyoid neck dissection in the management of cervical lymph node metastases of squamous cell carcinoma of the lower lip. Head Neck 2002; 24: 678-683 DOI: 10.1002/hed.10079.
• 119 Bhandari K, Wang D, Li S. et al. Primary cN0 lip squamous cell carcinoma and elective neck dissection: Systematic review and meta-analysis. Head Neck 2015; 37: 1392-1400 DOI: 10.1002/hed.23772.
• 120 Newlands C, Currie R, Memon A. et al. Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016; 130: S125-S132 DOI: 10.1017/S0022215116000554.
• 121 Martinez J-C, Jl Cook. High-Risk Cutaneous Squamous Cell Carcinoma without Palpable Lymphadenopathy: Is There a Therapeutic Role for Elective Neck Dissection?. Dermatologic Surgery 2007; 33: 410-420 DOI: 10.1111/j.1524-4725.2007.33087.x.
• 122 Amit M, Liu C, Mansour J. et al. Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer 2021; 127: 4413-4420 DOI: 10.1002/cncr.33773.
• 123 Peiffer N, Kutz JW, Myers LL. et al. Patterns of Regional Metastasis in Advanced Stage Cutaneous Squamous Cell Carcinoma of the Auricle. Otolaryngology–Head and Neck Surgery 2011; 144: 36-42 DOI: 10.1177/0194599810390908.
• 124 Ferlito A, Rinaldo A, Silver CE. et al. Elective and therapeutic selective neck dissection. Oral Oncol 2006; 42: 13-24 DOI: 10.1016/j.oraloncology.2005.03.009.
• 125 Audet N, Palme CE, Gullane PJ. et al. Cutaneous metastatic squamous cell carcinoma to the parotid gland: analysis and outcome. Head Neck 2004; 26: 727-732 DOI: 10.1002/hed.20048.
• 126 Rotman A, Kerr SJ, Giddings CEB. Elective neck dissection in metastatic cutaneous squamous cell carcinoma to the parotid gland: A systematic review and meta-analysis. Head Neck 2019; 41: 1131-1139 DOI: 10.1002/hed.25561.
• 127 Han A, Ratner D. What is the role of adjuvant radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion?. Cancer 2007; 109: 1053-1059 DOI: 10.1002/cncr.22509.
• 128 Gunaratne DA, Howle JR, Veness MJ. Sentinel lymph node biopsy in Merkel cell carcinoma: a 15-year institutional experience and statistical analysis of 721 reported cases. British Journal of Dermatology 2016; 174: 273-281 DOI: 10.1111/bjd.14240.
• 129 Stokes JB, Graw KS, Dengel LT. et al. Patients With Merkel Cell Carcinoma Tumors≤1.0 cm in Diameter Are Unlikely to Harbor Regional Lymph Node Metastasis. Journal of Clinical Oncology 2009; 27: 3772-3777 DOI: 10.1200/JCO.2008.20.8272.
• 130 Iyer JG, Storer BE, Paulson KG. et al. Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma. J Am Acad Dermatol 2014; 70: 637-643 DOI: 10.1016/j.jaad.2013.11.031.
• 131 Timmer FCA, Klop WMC, Relyveld GN. et al. Merkel cell carcinoma of the head and neck: emphasizing the risk of undertreatment. European Archives of Oto-Rhino-Laryngology 2016; 273: 1243-1251 DOI: 10.1007/s00405-015-3558-0.
• 132 Cheraghlou S, Agogo GO, Girardi M. Evaluation of Lymph Node Ratio Association With Long-term Patient Survival After Surgery for Node-Positive Merkel Cell Carcinoma. JAMA Dermatol 2019; 155: 803-811 DOI: 10.1001/jamadermatol.2019.0267.
• 133 Hong NJL, Wright FC, Gagliardi AR. et al. Examining the potential relationship between multidisciplinary cancer care and patient survival: An international literature review. J Surg Oncol 2010; 102: 125-134 DOI: 10.1002/jso.21589.
• 134 Lamb BW, Brown KF, Nagpal K. et al. Quality of Care Management Decisions by Multidisciplinary Cancer Teams: A Systematic Review. Ann Surg Oncol 2011; 18: 2116-2125 DOI: 10.1245/s10434-011-1675-6.
• 135 Bundesministerium für Gesundheit. Broschüre: Nationaler Krebsplan – Handlungsfelder, Ziele und Umsetzungsempfehlungen. Berlin. 2012
• 136 Ascierto PA, Schadendorf D. Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma. J Immunother Cancer 2022; 10: e005082 DOI: 10.1136/jitc-2022-005082.
• 137 Harrington C, Kwan W. Radiotherapy and Conservative Surgery in the Locoregional Management of Merkel Cell Carcinoma: The British Columbia Cancer Agency Experience. Ann Surg Oncol 2016; 23: 573-578 DOI: 10.1245/s10434-015-4812-9.
• 138 Takagishi SR, Marx TE, Lewis C. et al. Postoperative radiation therapy is associated with a reduced risk of local recurrence among low risk Merkel cell carcinomas of the head and neck. Adv Radiat Oncol 2016; 1: 244-251 DOI: 10.1016/j.adro.2016.10.003.
• 139 Becker JC, Ugurel S, Leiter U. et al. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial. The Lancet 2023; DOI: 10.1016/S0140-6736(23)00769-9.
• 140 Ferrarotto R, Nagarajan P, Maronge JM. et al. Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngology–Head & Neck Surgery 2023; DOI: 10.1001/jamaoto.2023.1729.
• 141 Gross ND, Miller DM, Khushalani NI. et al. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. New England Journal of Medicine 2022; 387: 1557-1568 DOI: 10.1056/NEJMoa2209813.
• 142 Topalian SL, Bhatia S, Amin A. et al. Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. Journal of Clinical Oncology 2020; 38: 2476-2487 DOI: 10.1200/JCO.20.00201.
• 143 Sekulic A, Migden MR, Oro AE. et al. Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma. New England Journal of Medicine 2012; 366: 2171-2179 DOI: 10.1056/NEJMoa1113713.
• 144 Migden MR, Guminski A, Gutzmer R. et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol 2015; 16: 716-728 DOI: 10.1016/S1470-2045(15)70100-2.
• 145 Lear JT, Migden MR, Lewis KD. et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. Journal of the European Academy of Dermatology and Venereology 2018; 32: 372-381 DOI: 10.1111/jdv.14542.
• 146 Stratigos AJ, Sekulic A, Peris K. et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol 2021; 22: 848-857 DOI: 10.1016/S1470-2045(21)00126-1.
• 147 Stratigos AJ, Sekulic A, Peris K. et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol 2021; 22: 848-857 DOI: 10.1016/S1470-2045(21)00126-1.
• 148 Rischin D, Khushalani NI, Schmults CD. et al. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer 2021; 9: e002757 DOI: 10.1136/jitc-2021-002757.
• 149 Hughes BGM, Munoz-Couselo E, Mortier L. et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Ann Oncol 2021; 32: 1276-1285 DOI: 10.1016/j.annonc.2021.07.008.
• 150 Hitt R, Irigoyen A, Cortes-Funes H. et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Annals of Oncology 2012; 23: 1016-1022 DOI: 10.1093/annonc/mdr367.
• 151 Glutsch V, Kneitz H, Gesierich A. et al. Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma. Cancer Immunology, Immunotherapy 2021; 70: 2087-2093 DOI: 10.1007/s00262-020-02832-0.
• 152 Nghiem P, Kaufman HL, Bharmal M. et al. Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncology 2017; 13: 1263-1279 DOI: 10.2217/fon-2017-0072.